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Abstract 
Chronic actinic dermatitis is a chronic photosensitivity disorder characterized by severe 
eczematous lesions on sun-exposed skin areas. We report a case of chronic actinic 
dermatitis presenting with leonine facies and secondary adrenal insufficiency, which was 
successfully treated with topical tacrolimus. The facial lesions dramatically improved 
after sun avoidance and topical tacrolimus application. After almost 20 years of oral 
corticosteroid therapy complicated with secondary adrenal insufficiency, we were able to 
switch treatment from systemic corticosteroids to topical tacrolimus to control the 
patient’s symptoms. 
 
Introduction 
Chronic actinic dermatitis (CAD) is a severe photosensitivity disease induced by UVB, 
UVA and occasionally visible light. This idiopathic photodermatosis typically affects 
elderly men. Clinical manifestations include eczematous lesions, infiltrated plaques and 
pruritic erythematous papules, which develop on light-exposed areas, particularly the 
face, neck and upper chest [1]. The severity of the disease in each individual depends on 
the degree of photosensitivity, ranging from chronic eczematous lesions to erythroderma. 
Histopathological findings usually show eczematous appearance but sometimes may 
resemble cutaneous lymphoma [2]. The diagnosis of CAD is based on the following 3 
criteria: persistent photodermatitis without history of exposure to known  
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photosensitizers, abnormal delayed erythemal responses to UVB and/or UVA and/or 
visible light, and a histological finding consistent with photodermatitis [3]. The 
pathophysiology of CAD remains unclear, but current evidence suggests a delayed-type 
hypersensitivity reaction to endogenous photo-induced allergens. Several treatment 
modalities have been proposed to induce long-term remission, such as systemic 
corticosteroid, azathioprine, and PUVA; however, the use of these treatment options has 
limited efficacy and is associated with severe side effects. 
Case Report 
A 37-year-old male farmer presented to our hospital with a 22-year history of itchy indurated facial 
erythematous plaques. He has been treated with oral corticosteroids (prednisolone 30–60 mg/day) with 
only temporary improvement. He had no history of exposure to any chemicals, plants, or perfumes. 
Additionally, he had no known underlying disease and there was no family history of similar skin 
conditions. 
Physical examination showed huge indurated lichenified erythematous infiltrative plaques on his 
forehead, nose, and both cheeks (fig. 1), and there were discrete erythematous papules on both 
forearms. A skin biopsy from a lesion of the left cheek was obtained and stained with HE. The biopsy 
specimen consisted of mounds of parakeratosis, spongiosis and epidermal hyperplasia associated with 
dense superficial inflammatory cell infiltrates, mainly lymphocytes, in the thickened papillary dermis. 
Routine laboratory findings were normal, except for a very low morning serum cortisol level (<1 μg/dl). 
Antinuclear antibody and anti-HIV tests were negative. Patch and photopatch testing (including 
analysis of common photoallergens such as sunscreen, fragrance, and sesquiterpene lactone) revealed no 
contact sensitivity (table 1). Phototesting was done on uninvolved skin. The patient’s minimal erythema 
dose to both UVA and UVB demonstrated a significantly reduced threshold for UVA (3 J/cm
2; 
reference value: 30 J/cm
2) and UVB-induced erythema (12 mJ/cm
2; reference value: 45–60 mJ/cm
2) for 
his skin phototype IV (fig. 2). After 4 months of topical tacrolimus therapy and sun avoidance by using 
sunscreen and wearing opaque clothes and a broad-brimmed hat, there was a significant improvement 
of his facial lesions (fig. 3). Remission of CAD could be maintained by topical tacrolimus, and the 
secondary adrenal insufficiency induced by exogenous corticosteroid therapy recovered after 
discontinuation of oral steroids. 
Discussion 
In this case, CAD with extensive leonine facies was successfully treated with 0.1% 
tacrolimus ointment twice daily. A clinically significant improvement of all lesions was 
observed after 4 months. There was no adverse effect except for a mild transient burning 
sensation during the first few treatment days. Tacrolimus is an immunosuppressive 
macrolide antibiotic, which inhibits calcineurin and suppresses the activation of antigen-
specific T cells and the release of inflammatory cytokines, such as interleukin 2 and tumor 
necrosis factor [4]. T cell activation may be important for the pathogenesis of CAD. This 
hypothesis is supported by both the fact that the infiltrating cells are predominantly T 
cells and the immunological effects of tacrolimus [5]. This advocates the use of topical 
tacrolimus as maintenance therapy and to prevent recurrence. After a follow-up period of 
1 year with strict sun protection and maintenance therapy with topical tacrolimus once 
daily, the patient eventually achieved remission. Although there have been several reports 
of CAD cases successfully treated with topical tacrolimus [5–8], this is the first case with 
severe and extensive leonine facies, which were uncontrolled despite 20 years of oral 
corticosteroid use, which in contrary induced secondary adrenal insufficiency as adverse  
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effect. After remission, the oral corticosteroid was successfully tapered and discontinued 
within 6 months; thereafter, the morning serum cortisol level returned to a normal range. 
In conclusion, this case demonstrates for the first time that topical tacrolimus might be 
an appropriate topical treatment with minimal side effects to induce and maintain 
remission in severe CAD cases. 
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Table 1. Photopatch test form 
48 h  72 h  96 h       Test 
No. 
Photopatch series 
 NR R   NR R   NR R   
Remarks 
                 
SU1 4-tert-Butyl-4’-methoxy-dibenzoylmethane 
(Parsol 1789) 2.0 pet B029 
  _  _  _  _  _  _                                   
SU2  4-Aminobenzoic acid (PABA) 5.0 pet A006    _  _  _  _  _  _                                   
SU3  4-Isopropyl-dibenzoylmethane (Eusolex 8020) 
2.0 pet I005 
  _  _  _  _  _  _                                   
SU4  3-(4-Methylbenzyliden) camphor (Eusolex 6300) 
2.0 pet M024 
  _  _  _  _  _  _                                   
SU5 2-Ethylhexyl-4-dimethylaminobenzoate  (Eusolex 
6007, Escalol 507) 2.0 pet E018 
  _  _  _  _  _  _                                   
SU6 2-Hydroxy-4-methoxybenzophenone  (Eusolex 
4360, Escalol 567, Oxybenzone) 2.0 pet H014 
  _  _  _  _  _  _                                   
SU7 2-Ethylhexyl-4-methoxycinnamate  (Parsol  MCX, 
Escalo 557) 2.0 pet E019 
  _  _  _  _  _  _                                   
SU8 2-Hydroxy-methoxymethylbenzophenone 
(Mexenone) 2.0 pet H020 
  _  _  _  _  _  _                                   
SU9 2-Phenylbenzimidazol-5-sulfonic  acid  (Eusolex 
232, Novantisol) 
  _  _  _  _  _  _                                   
SU10 2-Hydroxy-4-methoxybenzophenon-5-sulfonic 
acid (Sulisobenxone, Uvinyl MS-40, 
Benzophenone 4) 5.0 pet H023 
  _  _  _  _  _  _                                   
SU11  Trichlorcarbanilide (TCC) 1.0 pet T013    _  _  _  _  _  _                                   
SU12  Tribromsalicylanilide (TBS) 1.0 pet T012    _  _  _  _  _  _                                   
SU13  Musk ambrette 1.0 pet M017    _  _  _  _  _  _                                   
SU14  6-Methylcoumarine (6-MC) 1.0 pet M010    _  _  _  _  _  _                                   
SU15  Bithionol 1.0 pet B014    _  _  _  _  _  _                                   
SU16  Wood mix (pine, spruce, birch, teak) 
20.0 pet Mx09 
  _  _  _  _  _  _                                   
SU17 Tetrachlorsalicylanilide  (TCS) 0.1 pet T001    _  _  _  _  _  _                                   
SU18  Hexachlorophene 1.0 pet H001    _  _  _  _  _  _                                   
SU19  Diphenhydramine hydrochloride 1.0 pet D021    _  _  _  _  _  _                                   
SU20  Perfume mix 6.0 pet Mx08    _  _  _  _  _  _                                   
SU21  Diallyldisulfide 1.0 pet D048    _  _  _  _  _  _                                   
SU22 Chrysanthemum  cinerariaefolium 
(Pyrethrum) 1.0 pet C031 
  _  _  _  _  _  _                                   
SU23  Sesquiterpene lactone mix* 0.1 pet Mx18    _  _  _  _  _  _                                   
SU24  Lichen acid mix 0.3 pet  Mx15    _  _  _  _  _  _                                   
SU25  Sulfanilamide 5.0 pet S010    _  _  _  _  _  _                                   
SU26  T026 Thiourea 0.1% pet    _  _  _  _  _  _                                   
SU27  Quinidire 1% pet    _  _  _  _  _  _                                   
SU28  Naproxen 5% pet    _  _  _  _  _  _                                   
SU29  Ibuprofe 5% pet     _  _  _  _  _  _                                   
SU30  Diclofenac 1% pet    _  _  _  _  _  _                                   
SU31  Ketoprofen 2.5% pet    _  _  _  _  _  _                                   
SU32  Balsam Peru 25.0 pet B001    _  _  _  _  _  _                                   
SU33 2-tert-Butyl-4-methoxyphenol  (BHA) 
2.0 pet B022 
  _  _  _  _  _  _                                   
SU34  Chlorhexidine digluconate 0.5 aq C005    _  _  _  _  _  _                                   
 
 
  
Case Rep Dermatol 2011;3:49–54 
DOI: 10.1159/000325068 
Published online: 
February 25, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
53
 
Fig. 1. Before treatment. 
 
 
 
Fig. 2. Reduced threshold for UVA and UVB. 
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Fig. 3. After 6 months of treatment. 
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